PURPOSE: Pyrazoloacridine (PZA) is an acridine derivative selected for clinical development because of broad pre-clinical antitumor activity and solid tumor selectivity. Phase I evaluations with PZA have demonstrated predictable toxicity and suggested clinical efficacy. A phase II trial in patients with previously untreated advanced pancreatic cancer was conducted. METHODS: PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 21 days. Seventeen patients were treated receiving a total of 46 courses of PZA. RESULTS: Of the 15 patients evaluable for response, no responses were observed (0% response rate, 95% confidence interval 0-22%). Major toxicities directly attributable to PZA included moderate neutropenia and mild neurotoxicity. CONCLUSION: PZA at this dose and schedule of administration was inactive in patients with pancreatic carcinoma.
PURPOSE:Pyrazoloacridine (PZA) is an acridine derivative selected for clinical development because of broad pre-clinical antitumor activity and solid tumor selectivity. Phase I evaluations with PZA have demonstrated predictable toxicity and suggested clinical efficacy. A phase II trial in patients with previously untreated advanced pancreatic cancer was conducted. METHODS:PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 21 days. Seventeen patients were treated receiving a total of 46 courses of PZA. RESULTS: Of the 15 patients evaluable for response, no responses were observed (0% response rate, 95% confidence interval 0-22%). Major toxicities directly attributable to PZA included moderate neutropenia and mild neurotoxicity. CONCLUSION:PZA at this dose and schedule of administration was inactive in patients with pancreatic carcinoma.
Authors: P LoRusso; A J Wozniak; L Polin; D Capps; W R Leopold; L M Werbel; L Biernat; M E Dan; T H Corbett Journal: Cancer Res Date: 1990-08-15 Impact factor: 12.701
Authors: S Cullinan; C G Moertel; H S Wieand; A J Schutt; J E Krook; J F Foley; B D Norris; C G Kardinal; L K Tschetter; J F Barlow Journal: Cancer Date: 1990-05-15 Impact factor: 6.860
Authors: E K Rowinsky; D A Noe; L B Grochow; S E Sartorious; M K Bowling; T L Chen; B G Lubejko; S H Kaufmann; R C Donehower Journal: J Clin Oncol Date: 1995-08 Impact factor: 44.544
Authors: Alex A Adjei; Joel M Reid; Charles Erlichman; Jeff A Sloan; Henry C Pitot; Steven R Alberts; Richard M Goldberg; Lorelei J Hanson; Stacie Ruben; Scott A Boemer; Pamela Atherton; Matthew M Ames; Scott H Kaufmann Journal: Invest New Drugs Date: 2002-08 Impact factor: 3.850